Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Trial watch: Anticancer radioimmunotherapy
Erika Vacchelli
, Ilio Vitale
, Eric Tartour
,
Alexander Eggermont
, Catherine Sautès-Fridman
, Jérôme Galon
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel recenseren
›
peer review
83
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Trial watch: Anticancer radioimmunotherapy'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Abscopal Effect
33%
Adaptive Immune Response
33%
Adjuvant Chemotherapy
33%
Anticancer
100%
Anticancer Immune Response
66%
Antineoplastic Agents
33%
Bystander Effect
100%
Cancer Cells
33%
Cancer Patients
33%
Cancer-specific
33%
Cell-based
33%
Cell-extrinsic
33%
Clinical Efficacy
33%
Clinical Potential
33%
Clinical Trials
33%
Damage-associated Molecular Patterns
33%
Direct Transmission
33%
Extrinsic Mechanism
33%
Gap Junction
33%
Immunogenic
33%
Immunomodulatory
33%
Immunosuppressive Agents
33%
Immunotherapeutics
33%
In Cancer
33%
Irradiation
33%
Macromolecules
33%
Malignant Cells
66%
Monoclonal Antibody
33%
Neoadjuvant
33%
Neoadjuvant Setting
33%
Nitric Oxide
33%
Out-of-field
33%
Palliative Interventions
33%
Radioimmunotherapy
100%
Radiotherapy
100%
Radiotherapy Alone
33%
Reactive Oxygen Species
33%
Receptor Agonist
33%
Specific Damage
33%
Therapeutic Potential
33%
Toll-like
33%
Treatment Modalities
33%
Tumor Vasculature
33%
Tumor-specific
33%
Medicine and Dentistry
Abscopal Effect
25%
Adaptive Immunity
25%
Adjuvant
25%
Antineoplastic Activity
25%
Bystander Effect
75%
Cancer Cell
25%
Chemotherapy
25%
Clinical Trial
25%
Cytokine
25%
Dendritic Cell Vaccine
25%
Gap Junction
25%
Immune Response
50%
Immunomodulating Agent
25%
Malignant Neoplasm
75%
Mediator
25%
Monoclonal Antibody
25%
Nitric Oxide
25%
Radiation Therapy
100%
Radioimmunotherapy
100%
Reactive Oxygen Species
25%
Specific Tumor
25%
Toll Like Receptor Agonist
25%
Tumor Vascularization
25%
Immunology and Microbiology
Adaptive Immune System
33%
Adjuvant
33%
Agonist
33%
Antineoplastic Activity
33%
Bystander Effect
100%
Cancer Cell
33%
Cytokine
33%
Dendritic Cell Vaccine
33%
Gap Junction
33%
Immune Response
66%
Immunomodulating Drugs
33%
Macromolecule
33%
Mediator
33%
Monoclonal Antibody
33%
Toll-Like Receptor
33%
Tumor Vascularization
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
25%
Anticarcinogen
25%
Chemotherapy
25%
Clinical Trial
25%
Cytokine
25%
Dendritic Cell Vaccine
25%
Immunomodulating Agent
25%
Malignant Neoplasm
100%
Monoclonal Antibody
25%
Neoplasm
25%
Nitric Oxide
25%
Reactive Oxygen Metabolite
25%
Toll Like Receptor Agonist
25%
Tumor Vascularization
25%